Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Government agencies communicate via .gov.sg websites (e.g. go.gov.sg/open). Trusted websites
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary
A

Amivantamab

Availability of ACE Drug Guidance

Yes

Biologics Drug Information Overview

Yes

Subsidy Information and Financing Scheme

No

Active ingredient: Amivantamab

General information

Subsidy Information and Financing Scheme

Not Applicable

Drug Guidance for Subsidy

06/02/2026 Amivantamab for previously untreated, locally advanced or metastatic EGFR exon 20 insertion mutation-positive non-small-cell lung cancer

[NR] The Ministry of Health’s Drug Advisory Committee has not recommended amivantamab, in combination with platinum-based chemotherapy for inclusion on the MOH List of Subsidised Drugs for previously untreated, locally advanced or metastatic epidermal growth factor receptor (EGFR) exon 20 insertion mutation-positive non-small-cell lung cancer. The decision was based on the uncertain extent of clinical benefit, unfavourable cost effectiveness compared with platinum-based chemotherapy, and the unacceptable price-volume agreement proposed by the company.

Clinical indication, subsidy class and MediShield Life claim limit for amivantamab are provided in the Annex.

06/02/2026 Amivantamab for previously treated, locally advanced or metastatic EGFR exon 19 deletion or exon 21 L858R substitution mutation-positive non-small-cell lung cancer

[NR] The Ministry of Health’s Drug Advisory Committee has not recommended amivantamab, in combination with platinum-based chemotherapy, for inclusion on the MOH List of Subsidised Drugs for previously treated, locally advanced or metastatic epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutation-positive non-small-cell lung cancer. The decision was based on the uncertain extent of clinical benefit, unfavourable cost-effectiveness compared with platinum-based chemotherapy, and the unacceptable price-volume agreement proposed by the company.

Clinical indication, subsidy class and MediShield Life claim limit for amivantamab are provided in the Annex.

View legend

List of monographs containing this active ingredient

Amivantamab [Rybrevant]

Back to top